Literature DB >> 27468212

Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C.

Takafumi Saito1, Masahiro Sugimoto1, Kazuo Okumoto1, Hiroaki Haga1, Tomohiro Katsumi1, Kei Mizuno1, Taketo Nishina1, Sonoko Sato1, Kaori Igarashi1, Hiroko Maki1, Masaru Tomita1, Yoshiyuki Ueno1, Tomoyoshi Soga1.   

Abstract

AIM: To clarify the characteristics of metabolite profiles in virus-related hepatocellular carcinoma (HCC) patients using serum metabolome analysis.
METHODS: The serum levels of low-molecular-weight metabolites in 68 patients with HCC were quantified using capillary electrophoresis chromatography and mass spectrometry. Thirty and 38 of the patients suffered from hepatitis B virus-related HCC (HCC-B) and hepatitis C virus-related HCC (HCC-C), respectively.
RESULTS: The main metabolites characteristic of HCC were those associated with glutathione metabolism, notably 13 γ-glutamyl peptides, which are by-products of glutathione induction. Two major profiles, i.e., concentration patterns, of metabolites were identified in HCC patients, and these were classified into two groups: an HCC-B group and an HCC-C group including some of the HCC-B cases. The receiver operating characteristic curve for the multiple logistic regression model discriminating HCC-B from HCC-C incorporating the concentrations of glutamic acid, methionine and γ-glutamyl-glycine-glycine showed a highly significant area under the curve value of 0.94 (95%CI: 0.89-1.0, P < 0.0001).
CONCLUSION: The serum levels of γ-glutamyl peptides, as well as their concentration patterns, contribute to the development of potential biomarkers for virus-related HCC. The difference in metabolite profiles between HCC-B and HCC-C may reflect the respective metabolic reactions that underlie the different pathogeneses of these two types of HCC.

Entities:  

Keywords:  Glutathione; Hepatocellular carcinoma; Metabolome; Oxidative stress; γ-glutamyl peptides

Mesh:

Substances:

Year:  2016        PMID: 27468212      PMCID: PMC4945981          DOI: 10.3748/wjg.v22.i27.6224

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.

Authors:  Sumio Watanabe; Nobuyuki Enomoto; Kazuhiko Koike; Namiki Izumi; Hajime Takikawa; Etsuko Hashimoto; Fuminori Moriyasu; Hiromitsu Kumada; Michio Imawari
Journal:  Hepatol Res       Date:  2011-06-28       Impact factor: 4.288

2.  Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species.

Authors:  Hidetake Fujinaga; Takeya Tsutsumi; Hiroshi Yotsuyanagi; Kyoji Moriya; Kazuhiko Koike
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

3.  Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine).

Authors:  O W Griffith; A Meister
Journal:  J Biol Chem       Date:  1979-08-25       Impact factor: 5.157

4.  Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption.

Authors:  Tomoyoshi Soga; Richard Baran; Makoto Suematsu; Yuki Ueno; Satsuki Ikeda; Tadayuki Sakurakawa; Yuji Kakazu; Takamasa Ishikawa; Martin Robert; Takaaki Nishioka; Masaru Tomita
Journal:  J Biol Chem       Date:  2006-04-11       Impact factor: 5.157

Review 5.  Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Authors:  Masao Omata; Haruhiko Yoshida; Yasushi Shiratori
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

6.  Oxidative stress and antioxidant defense in patients with chronic hepatitis B.

Authors:  Nuriye Tasdelen Fisgin; Birsen Kilicoglu Aydin; Hanife Sarikaya; Esra Tanyel; Saban Esen; Mustafa Sunbul; Hakan Leblebicioglu
Journal:  Clin Lab       Date:  2012       Impact factor: 1.138

7.  Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis.

Authors:  Hongchang Gao; Qiang Lu; Xia Liu; Hui Cong; Liangcai Zhao; Huimin Wang; Donghai Lin
Journal:  Cancer Sci       Date:  2009-04       Impact factor: 6.716

8.  Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Authors:  Y Imai; S Kawata; S Tamura; I Yabuuchi; S Noda; M Inada; Y Maeda; Y Shirai; T Fukuzaki; I Kaji; H Ishikawa; Y Matsuda; M Nishikawa; K Seki; Y Matsuzawa
Journal:  Ann Intern Med       Date:  1998-07-15       Impact factor: 25.391

9.  Metabolomic profile of hepatitis C virus-infected hepatocytes.

Authors:  Barbara Roe; Elizabeth Kensicki; Robert Mohney; William W Hall
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

Review 10.  Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.

Authors:  Monica Marra; Ignazio M Sordelli; Angela Lombardi; Monica Lamberti; Luciano Tarantino; Aldo Giudice; Paola Stiuso; Alberto Abbruzzese; Rossella Sperlongano; Marina Accardo; Massimo Agresti; Michele Caraglia; Pasquale Sperlongano
Journal:  J Transl Med       Date:  2011-10-10       Impact factor: 5.531

View more
  3 in total

1.  Metabolic signature of healthy lifestyle and its relation with risk of hepatocellular carcinoma in a large European cohort.

Authors:  Nada Assi; Marc J Gunter; Duncan C Thomas; Michael Leitzmann; Magdalena Stepien; Véronique Chajès; Thierry Philip; Paolo Vineis; Christina Bamia; Marie-Christine Boutron-Ruault; Torkjel M Sandanger; Amaia Molinuevo; Hendriek Boshuizen; Anneli Sundkvist; Tilman Kühn; Ruth Travis; Kim Overvad; Elio Riboli; Augustin Scalbert; Mazda Jenab; Vivian Viallon; Pietro Ferrari
Journal:  Am J Clin Nutr       Date:  2018-07-01       Impact factor: 7.045

Review 2.  Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.

Authors:  Serena De Matteis; Andrea Ragusa; Giorgia Marisi; Stefania De Domenico; Andrea Casadei Gardini; Massimiliano Bonafè; Anna Maria Giudetti
Journal:  Oxid Med Cell Longev       Date:  2018-11-04       Impact factor: 6.543

3.  Metabolomic biomarkers for hepatocellular carcinoma: A systematic review.

Authors:  Ningning Feng; Fatao Yu; Feng Yu; Yuling Feng; Xiaolin Zhu; Zhihui Xie; Yi Zhai
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.